236 related articles for article (PubMed ID: 24072883)
41. Protein C and its inhibitor in malignancy.
Suzuki K; Hayashi T
Semin Thromb Hemost; 2007 Oct; 33(7):667-72. PubMed ID: 18000793
[TBL] [Abstract][Full Text] [Related]
42. Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells.
Kang J; Kim W; Kwon T; Youn H; Kim JS; Youn B
Oncotarget; 2016 Apr; 7(17):23961-74. PubMed ID: 27004408
[TBL] [Abstract][Full Text] [Related]
43. The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.
Maione F; Oliaro-Bosso S; Meda C; Di Nicolantonio F; Bussolino F; Balliano G; Viola F; Giraudo E
Sci Rep; 2015 Mar; 5():9054. PubMed ID: 25761781
[TBL] [Abstract][Full Text] [Related]
44. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.
Cejka D; Preusser M; Woehrer A; Sieghart W; Strommer S; Werzowa J; Fuereder T; Wacheck V
Cancer Biol Ther; 2008 Sep; 7(9):1377-85. PubMed ID: 18708754
[TBL] [Abstract][Full Text] [Related]
45. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
46. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
Soff GA; Sanderowitz J; Gately S; Verrusio E; Weiss I; Brem S; Kwaan HC
J Clin Invest; 1995 Dec; 96(6):2593-600. PubMed ID: 8675623
[TBL] [Abstract][Full Text] [Related]
47. Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells.
Ramer R; Rohde A; Merkord J; Rohde H; Hinz B
Pharm Res; 2010 Oct; 27(10):2162-74. PubMed ID: 20668920
[TBL] [Abstract][Full Text] [Related]
48. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
[TBL] [Abstract][Full Text] [Related]
49. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
Kim E; Tunset HM; Cebulla J; Vettukattil R; Helgesen H; Feuerherm AJ; Engebråten O; Mælandsmo GM; Johansen B; Moestue SA
BMC Cancer; 2016 Mar; 16():191. PubMed ID: 26951085
[TBL] [Abstract][Full Text] [Related]
50. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
51. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.
McMahon GA; Petitclerc E; Stefansson S; Smith E; Wong MK; Westrick RJ; Ginsburg D; Brooks PC; Lawrence DA
J Biol Chem; 2001 Sep; 276(36):33964-8. PubMed ID: 11441025
[TBL] [Abstract][Full Text] [Related]
52. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
53. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
54. Harmine suppresses bladder tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
Hai-Rong C; Xiang H; Xiao-Rong Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30910851
[TBL] [Abstract][Full Text] [Related]
55. Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors.
Stalin J; Nollet M; Garigue P; Fernandez S; Vivancos L; Essaadi A; Muller A; Bachelier R; Foucault-Bertaud A; Fugazza L; Leroyer AS; Bardin N; Guillet B; Dignat-George F; Blot-Chabaud M
Oncogene; 2016 Oct; 35(42):5489-5500. PubMed ID: 27065325
[TBL] [Abstract][Full Text] [Related]
56. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Fang H; Jin J; Huang D; Yang F; Guan X
Cancer Sci; 2018 Jun; 109(6):1949-1957. PubMed ID: 29601121
[TBL] [Abstract][Full Text] [Related]
57. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.
Kubala MH; DeClerck YA
Cancer Metastasis Rev; 2019 Sep; 38(3):483-492. PubMed ID: 31734763
[TBL] [Abstract][Full Text] [Related]
58. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
Huynh H; Ong R; Zopf D
J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
[TBL] [Abstract][Full Text] [Related]
59. The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth.
Bellou S; Karali E; Bagli E; Al-Maharik N; Morbidelli L; Ziche M; Adlercreutz H; Murphy C; Fotsis T
Mol Cancer; 2012 May; 11():35. PubMed ID: 22583931
[TBL] [Abstract][Full Text] [Related]
60. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
